Jiangsu Hengrui Pharmaceuticals and its partner Elevar Therapeutics will have to wait even longer before their PD-1 inhibitor ...

This week, the FDA approved J&J’s JNJ Tremfya for its second inflammatory bowel disease (“IBD”) condition, Crohn’s disease ...

BEIJING] AstraZeneca will invest US$2.5 billion in a new research centre in Beijing, in a major show of commitment to China ...

Despite resubmitting after an initial complete response letter (CRL) due to manufacturing issues, the combination therapy ...

AstraZeneca (AZN) said Friday it plans to invest $2.5 billion in a new research and development hub in China as the drugmaker tries to reignite ...

AstraZeneca Plc will invest $2.5 billion in a new research center in Beijing, in a major show of commitment to China just ...

British pharmaceutical giant AstraZeneca announced on Friday that it will invest $2.5 billion in a research and development ...

AstraZeneca (AZ) has announced that its immunotherapy Imfinzi (durvalumab) has been approved by the European Commission (EC) ...

IntroductionProgrammed cell death protein 1 (PD-1) and its ligand, PD-L1, are crucial immune checkpoints that regulate the ...

Independent Advisor Alliance increased its holdings in AstraZeneca PLC (NASDAQ:AZN – Free Report) by 13.0% in the fourth ...

IMFINZITM (durvalumab) has received approval in the European Union as a monotherapy for treating adults with limited-stage ...